PI3K alpha inhibitor - OnKure Therapeutics
Alternative Names: Phosphatidylinositol 3-kinase alphaE542K, E545K inhibitor - OnKure Therapeutics; PI3KαE542K, E545K inhibitor - OnKure TherapeuticsLatest Information Update: 03 May 2024
At a glance
- Originator OnKure Therapeutics
- Class Antineoplastics
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 26 Apr 2024 Early research in Cancer in USA (unspecified route) prior to April 2024 (OnKure Therapeutics pipeline, April 2024)